# BSI SA

> BSI SA is a VC fund in Lugano backing Biopharma, Health Care and Therapeutics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Lugano, Switzerland
- Total investments: 2
- Last investment: Jan 2010
- Lead investor: 0%
- Last updated: Aug 2026
- X (Twitter): https://www.twitter.com/bsibank
- Website: http://www.bsibank.com
- Facebook: https://www.facebook.com/efginternational

BSI SA is a VC fund in Lugano focused on Biopharma and Health Care. BSI SA provides asset management and related services to private and institutional clients in Switzerland and internationally. The company offers services relating to asset management, including investment funds; placing of fiduciary deposits; and trading in currencies and securities, precious metals, and foreign exchange. Its services includecorporate finance services, such as services for mergers and acquisitions, capital markets, and business evaluations; and life insurance solutions as an agent. The company also offers financial planning, advisory, and credit services. As of December 31, 2008, it operated through a network of seven branches in Switzerland; seven representative offices in Athens, Buenos Aires, Hong Kong, Montevideo, Panama, Taipei, and Bahrain; and six banks in Bahamas, Luxembourg, Madrid, Monte Carlo, Paris, and Singapore. The company was founded in 1873 and is headquartered in Lugano, Switzerland. BSI SA operates as a subsidiary of Participatie Maatschappij Graafschap Holland N.V.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GlobeImmune | GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediatedcancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado. | $17.5M | Series E | Jan 19, 2010 |  |
| Telormedix | Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $19M | Series A | Sep 30, 2008 |  |

2 of 2 investments shown.

## Co-investors
- [Aravis Ventures](https://shizune.co/investors/profile/aravis-ventures) — VC Fund, 1 deal together
- Generali Financial Holding — VC Fund, 1 deal together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 1 deal together
- [ProQuest Investments](https://shizune.co/investors/profile/proquest-investments) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does BSI SA invest in?

BSI SA invests primarily in Biopharma, Health Care and Therapeutics startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did BSI SA last invest?

The most recent investment recorded for BSI SA closed in Jan 2010. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co